Table 2 Characteristics of the included studies
First author and year of publication | Intervention measures in the control group | Intervention measures in the observation group | The number of cases in the control group | The number of cases in the observation group | Gender (female/male) | Ages in the control group | Ages in the observation group | Course of treatment | Follow-up time | Outcome indicators |
|---|---|---|---|---|---|---|---|---|---|---|
Chong Yan (2022) [12] | Placebo | Batoclimab 340 mg/ batoclimab 680 mg | 9 | 340 mg: 10 680 mg: 11 | 24/6 | 40.2 ± 9.3 | 340 mg: 36.4 ± 9.8 680 mg: 40.6 ± 16.8 | 43 days | 120 days | abcde |
Chong Yan (2024) [13] | Placebo | Batoclimab | 65 | 67 | 88/43 | 43.7 ± 13.5 | 43.8 ± 13.9 | 6 weeks | 4 weeks | abcde |
James F. Howard Jr. (2019) [14] | Placebo | Efgartigimod | 12 | 12 | 15/9 | 43.5 ± 19.3 | 55.3 ± 13.6 | 78 days | 2 weeks | abcde |
James F. Howard Jr. (2021) [15] | Placebo | Efgartigimod | 64 | 65 | 118/49 | 48.2 ± 15.0 | 45.9 ± 14.4 | 8 weeks | 5 weeks | abcde |
Vera Bri (2021) [16] | Placebo | Rozanolixizumab | 22 | 21 | 27/16 | 53.3 ± 15.7 | 50.5 ± 14.7 | 29 days | 70 days | abce |
James F. Howard Jr. (2017) [17] | Placebo | Eculizumab | 63 | 62 | 82/43 | 46.9 ± 18.0 | 47.5 ± 15.7 | 26 weeks | 8 weeks | abcde |
James F. Howard Jr. (2020)[18] | Placebo | Zilucoplan 0.1 mg/kg Zilucoplan 0.3 mg/kg | 15 | 0.1 mg/kg: 15 0.3 mg/kg: 14 | 21/23 | 48.4 ± 15.7 | 0.1 mg/kg: 45.5 ± 15.7 0.3 mg/kg: 54.6 ± 15.5 | 12 weeks | 60 weeks | abcde |
Tuan Vu (2022) [19] | Placebo | Ravulizumab | 89 | 86 | 89/86 | 53.3 ± 16.1 | 62.6 ± 11.2 | 26 weeks | 4 years | abde |
Karen Hewett (2018) [20] | Placebo | Belimumab 10 mg/kg | 21 | 18 | 24/15 | 59.0 ± 13.88 | 52.7 ± 17.32 | 20 weeks | 24 weeks | abce |
Fredrik Piehl (2022) [21] | Placebo | Rituximab 500 mg | 22 | 25 | 14/33 | 58 ± 18.6 | 67.4 ± 13.4 | 1 day | 24 weeks | abde |
Richard J. Nowak (2022) [22] | Placebo | Rituximab | 27 | 25 | 23/29 | 56.8 ± 17 | 53.2 ± 17.5 | 4 weeks | 24 weeks | abcde |